Study on the influence of Topiroxostat on renal function

Study on the influence of Topiroxostat on renal function - Study on the influence of Topiroxostat on renal function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034118

Enrollment

100

Registered

2018-09-25

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as hyperuricemia 2. Patients with hyperuricemia who have already administered topiroxostat more than 6 months at the start of the study 3. Patients who have test results of eGFR value or age, sex, serum creatinine value necessary for calculation of eGFR within 3 months before and after start of administration of topiroxostat

Exclusion criteria

Exclusion criteria: 1. Patients with history of hemodialysis or peritoneal dialysis within 3 months before or after the administration of topiroxostat, or before eGFR of less than 30, or before the start date of topioxastat administration 2. Patients taking other uric acid-lowering drugs (Febuxostat, Allopurinol, Benzbromarone, Probenecid, Bucolome) (including switching from other uric acid lowering drugs)

Design outcomes

Primary

Measure	Time frame
eGFR change amount from pre-administration value 6 months after administration	—

Secondary

Measure	Time frame
Change rate of eGFR Amount of change in urine albumin Serum uric acid Adverse event	—

Countries

Japan

Contacts

Public ContactYasuo Sato

Sato Clinic Internal medicine ,gastrointestinal medicine

yasuo@sato-clinic.tokyo03-5447-2477

Outcome results